Inici › Càncer de pròstata › Virgínia › Charlottesville
Assaigs clínics de Càncer de pròstata a Charlottesville, VA
15 estudis de Càncer de pròstata busquen participants en centres de Charlottesville i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
ReclutantFase 3
- University of Virginia Health System ( Site 0054), Charlottesville
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
ReclutantFase 3
- University of Virginia Comprehensive Cancer Center, Charlottesville
- University of Virginia, Charlottesville
- UVA Health Cancer Care Pantops, Charlottesville
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
ReclutantFase 3
- University of Virginia Cancer Center, Charlottesville
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
ReclutantFase 2
- University of Virginia Cancer Center, Charlottesville
The Vanguard Study: Testing a New Way to Screen for Cancer
ReclutantVoluntaris sans benvinguts
- Sentara Martha Jefferson Hospital, Charlottesville
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
ReclutantFase 3
- University of Virginia Cancer Center, Charlottesville
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ReclutantFase 2
- University of Virginia Comprehensive Cancer Center, Charlottesville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
ReclutantFase 1/2
- University of Virginia, Charlottesville
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
ReclutantFase 3
- University of Virginia Cancer Center, Charlottesville
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
ReclutantFase 1/2
- University of Virginia, Charlottesville
A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)
Reclutant
- University of Virginia Health System, Charlottesville
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
ReclutantEstudi observacional
- University of Virginia, Charlottesville
Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)
Reclutant
- University of Virginia, Charlottesville
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
ReclutantFase 1
- University of Virginia Cancer Center, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Charlottesville
Assaigs de Càncer de pròstata en altres ciutats
- New York City, NY103 estudis
- Houston, TX76 estudis
- Los Angeles, CA61 estudis
- Boston, MA59 estudis
- St. Louis, MO46 estudis
- Chicago, IL45 estudis
- San Francisco, CA45 estudis
- Philadelphia, PA44 estudis
- Baltimore, MD43 estudis
- Nashville, TN42 estudis
- Seattle, WA42 estudis
- Washington, DC38 estudis
Altres estudis a Charlottesville
- Càncer de pulmó de cèl·lules no petites21 estudis
- Leucèmia mieloide aguda16 estudis
- Càncer metastàtic13 estudis
- Càncer d'endometri13 estudis
- Càncer (tots els tipus)13 estudis
- Càncer de pulmó13 estudis
- Insuficiència cardíaca11 estudis
- Càncer d'ovari10 estudis
- Càncer colorrectal10 estudis
- Diabetis tipus 19 estudis
- Càncer de mama9 estudis
- Càncer de pàncrees9 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.